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Structural data on the SARS-CoV-2 main protease in complex with a
zinc-containing organic inhibitor are already present in the literature
and gave hints on the presence of a zinc binding site involving the
catalytically relevant cysteine and histidine residues. In this paper, the
structural basis of ionic zinc binding to the SARS-CoV-2 main protease
has been elucidated by X-ray crystallography. The zinc binding affinity
and its ability to inhibit the SARS-CoV-2 main protease have been
investigated. These findings provide solid ground for the design of
potent and selective metal-conjugated inhibitors of the SARS-CoV-2
main protease.
The SARS-CoV-2 main protease (SARS-CoV-2 Mpro), also referred
to as 3-chymotrypsin-like protease (SARS-CoV-2 3CLpro) or nsp5
is a cysteine protease that hydrolyses viral polyproteins at
several sites with a preference for the Leu-Gln (Ser, Ala, Gly)
sequences.1 The protein exhibits 96% sequence identity and
a very high structural similarity with the SARS-CoV Mpro
protein.2,3 The enzyme represents one of the main drug-target
candidates for covid-19 infection because it features a large
and deep pocket at the active site and is crucial for viral
replication.3–5 Presently more than 280 crystal structures of
SARS-CoV-2 Mpro with covalently or non-covalently bound inhi-
bitors or chemical fragments have been deposited into the
protein data bank (PDB, https://www.rcsb.org/). The active form
of the enzyme is a homodimer (67.6 kDa) where the N-terminal
region of each monomer interacts with the Glu166 of the other,
thus promoting and stabilizing binding of the substrate.3,4 The
active sites in each monomer face away from one another and
are formed by a Cys-His dyad (Cys 145 and His 41). The
hydrolysis of the substrate takes place in two main steps named
acylation and deacylation. During the first step, an acyl–enzyme
complex is formed, via a covalent bond with the Sg atom of Cys
145, with the release of a fragment of the substrate. During
deacylation, the acyl–enzyme complex is released by the action
of a water molecule, thus recovering the protease to its active
state for a new catalytic cycle.6,7 Several inhibitors of SARS-CoV
and SARS-CoV-2 Mpro have been designed that interfere with
the formation of the acyl–enzyme complex due to the promo-
tion of a covalent bond between the thiol group of the catalytic
cysteine and the inihibitor.3,4,8
A similar approach has been exploited using zinc-coordinating
inhibitors,9,10 where the zinc ion plays a role in stabilizing the
protein–inhibitor complex through a tetrahedral coordination
shared by the active site cysteine and histidine with two donor
atoms of the inhibitor. The solved experimental structures9–11
however leave open interesting questions concerning the zinc
binding ability of the protease in the cellular environment, even
in the absence of a coordinating ligand, and the possible role of
zinc ions in modulating its biological activity. Moreover, a recently
published bioinformatics study12 stimulated our interest on the
possible role of zinc in covid-19 infection and therapy.13
Zinc is second to iron as the most abundant transition metal
ion in living organisms.14 In eukaryotes, 9–10% of proteins are
zinc-binding proteins that depend on this metal ion to carry out
their biological function. Zinc is involved in proliferation, cell
signaling, differentiation, oxidative stress and immune response
and many other cellular processes.15,16 It is well known that
extracellular and intracellular zinc levels are tightly regulated in
such a way that free zinc ions (Zn2+) represent a minimal fraction
of total cellular zinc (B0.0001%).17–20 Furthermore, zinc ions are
not homogeneously distributed within the cells, with large differ-
ences among cellular compartments and organelles.21,22
Zinc has a key role in the signalling pathways of the innate
and adaptive immune reactions.23,24 It has been reported that
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zinc is able to participate in many processes of defense against
infections.25 Experimental and clinical evidence exists that
assesses zinc as a direct antiviral, as well as a stimulant of
antiviral immunity. For example, in vitro replication of the
influenza virus is significantly decreased by the addition of
the zinc ionophore pyrrolidine dithiocarbamate.26 Likewise,
severe acute respiratory syndrome (SARS) coronavirus RdRp
template binding and elongation was inhibited by zinc in Vero-
E6 cells.27 Furthermore, zinc salts were shown to inhibit
respiratory syncytial virus.28 Therefore, the supplementation
of zinc has been proposed to treat viral infections. In particular,
the role of zinc as an antiviral could be dual: on one side, zinc
supplementation could improve the antiviral response and
systemic immunity in patients with zinc deficiency,29 and, on
the other side, zinc treatment could inhibit viral replication or
infection-related symptoms.30
In this respect, advances in understanding the role of zinc in
covid-19 pathogenesis require the characterization of the viral
zincosome, and particularly how the different SARS-CoV-2
proteins interact with this metal ion.
Here, we provide an important piece of the puzzle by
reporting the X-ray structure of SARS-CoV-2 Mpro both in the
apo form and in complex with an isolated zinc ion, and an
extensive biophysical analysis of the metal–protein interaction
properties in solution.
Crystals of apo SARS-CoV-2 Mpro were soaked for two days
with 1.5 mM of the zinc ion solution (see the ESI† and Fig. S1
for experimental details). The apo protein structure discussed
in this paper is totally superimposable with the others already
deposited in the PDB along the entire sequence. The structure
of Zn-bound SARS-CoV-2 Mpro (ESI,† Fig. S2) resembles that of
the apo protein with average backbone and heavy atom RMSD
values of 0.19 Å and 0.64 Å, respectively. Only the local loop
regions showed backbone RMSD values higher than average
(ESI,† Fig. S3). The electron density for the zinc ion is very well
defined and the metal is present at full occupancy (Fig. 1a).
The zinc ion is coordinated by the sulfur atom of Cys145, the
Ne atom of the imidazole ring of His41, a well-defined water
molecule and a more labile one shuttling between two posi-
tions, thus completing a tetrahedral geometry. This is the first
structure with a zinc ion bound to coronavirus Mpro (or homo-
logous proteins in other viruses) as a cation, rather than as part
of a coordination compound. Comparison of the present struc-
ture with that of apo SARS-CoV-2 Mpro shows that the residues
involved in zinc binding do not undergo a significant structural
rearrangement, supporting the idea that the binding site is
ready to accommodate the metal (Fig. 1b and ESI,† Fig. S4).
The interaction of SARS-CoV-2 Mpro with the zinc ion has
been also investigated in solution using NMR. 15N isotopically
enriched protein samples (at a concentration of 130 mM as the
monomer) were titrated with the zinc ion and monitored using
1D 1H and 2D 1H–15N TROSY HSQC NMR spectroscopy (Fig. 2).
Spectral changes were observed that indicate an intermediate-
to-slow regime on the NMR time scale between the free and
bound forms. Fig. 2b shows the methyl signal for both the
apo- and metal-bound forms in a slow exchange regime.
This observation indicates that the zinc ion binds SARS-CoV-2
Mpro in solution.
To estimate the affinity of the zinc ion for the protein and to
investigate its effect on the proteolytic activity of the enzyme, a
fluorimetric assay was carried out by monitoring the fluores-
cence increase due to the hydrolysis of the peptide substrate
(Mca–AVLQ k SGFR-K(Dnp)K).4 The addition of zinc ions
inhibits the proteolytic activity of the enzyme, which is consis-
tent with the interaction of zinc with the protein active site
in solution. The fit of the kinetic data provided a Ki value of
0.58  0.19 mM (see ESI,† Fig. S5 and Fig. 3).
The binding capability of SARS-CoV-2 Mpro towards the zinc
ion is not completely unexpected as homologous proteases are
reported to bind a zinc ion, not in its ionic form but as a metal-
conjugated ligand. A comparison of the present structure with
those of homologous proteases expressed by other viruses
closely related to SARS-CoV-2 such as SARS-CoV (2Z9J, 2Z9K,
2Z9L, 2Z9G and 2Z94), Coxsackievirus B3 (2ZTX), HCoV-229E
(2ZU2) and with the only report in the literature of a SARS-CoV-
2 Mpro structure bound with zinc pyrithione (7B83) showed
that, overall, the zinc binding site is well maintained with non-
significant deviations from one structure to another (Fig. 4).
The zinc binding site has been also compared with that of
other non-viral cysteine-proteases reported to bind zinc, such
as cathepsin S both in the metal-bound and metal-free state
(2HH5 and 2HHN), or enzymes such as dimethylarginine
dimethylaminohydrolase I (2CI7). The structural features of
Fig. 1 (a) 2Fo Fc electron density map contoured at the 1s level showing
the zinc binding site in zinc bound SARS-COV-2 Mpro. The zinc ion is
shown as a magenta sphere, the water molecules are shown as red speres.
(b) Superposition of zinc bound SARS-COV-2 Mpro (light blue) and
SARS-COV-2 apo Mpro (pink) showing zinc (magenta) coordinated by
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the zinc binding site in these systems are very similar to those
of SARS-CoV-2 Mpro.
The structural analysis and the inhibition activity of zinc
towards SARS-CoV-2 Mpro suggest interesting considerations on
how the metal ion and the viral protease could interplay in the
cells. The affinity of the protein for zinc, although high, appears
to be not sufficient to inactivate SARS-CoV-2 Mpro as almost all the
intracellular zinc ion is bound to other proteins with similar or
higher affinity. This is confirmed by the efficient viral replication
and spreading of covid-19 infection and by the observation that
proteins bearing the same metal binding site such as cathepsin S
are highly active inside cells. For the same reasons, the potential
use of zinc supplementation for SARS-CoV-2 Mpro inhibition does
not seem viable. In particular, the presence of many zinc-binding
proteins with similar or higher affinity would make a selective
inhibition of SARS-CoV-2 Mpro by zinc supplementation unlikely.
More promising for SARS-CoV-2 Mpro inhibition would be the
design of suitable metallodrugs that incorporate zinc. A zinc-
containing organic or peptidomimetic molecule, by simulta-
neously interacting with the catalytically relevant Cys-His dyad
and with neighbouring additional sites or allosteric sites,11 could
be the basis for the design of inhibitors with low nanomolar
affinity for SARS-CoV-2 Mpro.31,32 This is not the case for zinc-
pyrithione where the organic fragments stick-out from the protein
surface without establishing any significant interaction with the
protein (Fig. S6, ESI†). In contrast, the combination of the
inhibitory effect of zinc with that of a molecule interacting with
residues surrounding the catalytic dyad can be a strategy for the
design of promising inhibitors. A similar approach has been
exploited to develop inhibitors of zinc-dependent matrix metallo-
proteinases.33,34 In addition, our results suggest that drugs based
on alternative metal ions, such as platinum or gold, could be
investigated as potential SARS-CoV-2 Mpro inhibitors considering
they are well established binders of cysteine thiolates.35,36
In summary, the present study highlights that a zinc ion
inhibits SARS-CoV-2 Mpro by binding at the active site in a
similar way to that observed for other cysteine proteases. The
affinity of the protein for the metal ion has been experimentally
determined and it does not seem high enough for any real
therapeutic application of zinc supplementation, at least in its
ionic state. However, our results suggest that a zinc ion coordi-
nated to suitable ligands capable of interacting with additional
sites on the protein surface could provide a significant increase
in binding affinity, thus allowing the design of potent and more
selective inhibitors of SARS-CoV-2 Mpro.
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Fig. 2 (a) Superposition of 2D 1H-15N TROSY HSQC spectra of apo SARS-
CoV-2 Mpro (black) and zinc-bound Mpro at a 1.2 : 1 Zn2+ : Mpro ratio (red);
(b) detail of the methyl region of the 1D 1H NMR spectra showing Mpro
titration with Zn2+.
Fig. 3 Zinc inhibits the activity of SARS-CoV-2 Mpro. The hydrolytic
activity of SARS-CoV-2 Mpro was measured in the presence of increasing
concentrations of the zinc ion. Three independent measurements are
shown as red circles, blue triangles and black squares, respectively. The Ki
values were determined using nonlinear regression.
Fig. 4 Superposition of the zinc binding site in zinc bound SARS-COV-2
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